EndPoints: GreenLight Biosciences celebrates manufacturing milestone

GreenLight Biosciences first commercial-scale engineering run of its Covid-19 vaccine booster candidate with Samsung was reported in EndPoints News as a manufacturing milestone. In an interview with the publication, GreenLight CEO Andrey Zarur said:

“The beauty of our platform is that once we have that we have ensured that whatever the leading candidate is that we liked at that microscopic scale is fully scalable to produce hundreds of millions of doses very rapidly,” he aid. “So, the value of the manufacturing platform itself gets amplified, if you will, by the fact that we have this upstream discovery engine.”

Read the full article here.

Find out more about how GreenLight manufactures RNA.